NAYO Biotechnology
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing integrated cell and gene therapy platforms for next-generation cancer treatments.
Oncology
Technology Platform
An integrated platform for engineering immune cells using gene therapy vectors and editing technologies to create enhanced cancer therapies.
Opportunities
Potential to address significant unmet needs in solid tumors and create durable, potentially curative treatments for cancer patients.
Risk Factors
Faces substantial technical and regulatory hurdles related to gene therapy safety, manufacturing complexity, and high cost of goods.
Competitive Landscape
Enters a competitive field dominated by well-funded players, requiring distinct technological advantages in cell engineering or novel targets to stand out.